RUTHERFORD, N.J., March 27, 2026
GlucoTrack announced plans to submit an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration in early Q2 2026 to initiate a U.S. clinical trial for its novel continuous blood glucose monitoring (CBGM) technology, following a series of critical 2025 operational and clinical milestones that position the company for regulatory advancement in the highly competitive diabetes device market.
Clinical Progress and First-in-Human Results
The company’s development momentum is anchored by the successful completion of its first-in-human clinical study conducted in Brazil, where ten participants with Type 1 and Type 2 diabetes underwent evaluation of the implantable CBGM system
The study demonstrated strong clinical performance, achieving all primary and secondary endpoints with a Mean Absolute Relative Difference (MARD) of 7.7%, a 99% data capture rate, and no serious device-related adverse events, indicating a favorable safety and accuracy profile. Notably, the system measures glucose directly from blood rather than interstitial fluid, effectively eliminating lag time, a key limitation in traditional glucose monitoring systems
In parallel, a feasibility study in Australia provided additional validation and enabled protocol and product refinements, strengthening the company’s readiness for larger-scale trials and regulatory submission.
Advertisement
U.S. Trial Readiness and Regulatory Strategy
Building on international clinical data, Glucotrack has advanced multiple U.S. clinical trial readiness activities, including securing a clinical trial site and partnering with a specialized Clinical Research Organization (CRO) experienced in diabetes-focused MedTech studies.
The company has also completed targeted product design enhancements to improve functionality and long-term performance. Engagements with the FDA are already underway to align on the clinical development pathway, with the company aiming to initiate its U.S. study in the second half of 2026, contingent upon IDE approval.
This planned submission represents a critical regulatory milestone, transitioning the technology from early-stage validation to formal U.S. clinical evaluation, a necessary step toward commercialization.
Technology Differentiation and Market Positioning
Glucotrack’s CBGM system is designed as a long-term, fully implantable glucose monitoring solution with a projected sensor lifespan of up to three years, eliminating the need for frequent sensor replacements or external wearable components. This positions the technology as a potential next-generation alternative to existing continuous glucose monitoring systems. The company has reinforced its innovation strategy through the issuance of three U.S. patents (USPTO) covering key aspects such as sensor chemistry, intravascular lead design, and low-power electronics, strengthening its intellectual property portfolio and competitive positioning.
Additionally, Glucotrack has established a dual-source U.S. manufacturing strategy and conducted extensive market research, identifying significant unmet demand for implantable solutions in a rapidly growing global diabetes market. With competitors including major industry players, the company’s differentiation lies in its fully implantable design and direct blood glucose measurement capability, which could offer improved accuracy and patient convenience.
Commercial Outlook and Strategic Significance
The planned IDE submission marks a pivotal inflection point for Glucotrack as it moves closer to entering the U.S. clinical landscape, one of the most critical markets for diabetes technologies. The company’s progress reflects a broader industry trend toward minimally invasive and long-duration monitoring solutions, addressing both patient compliance and clinical accuracy challenges. While the announcement remains forward-looking and dependent on regulatory approval, the combination of validated clinical data, regulatory engagement, and infrastructure readiness positions Glucotrack to advance its CBGM platform toward commercialization. If successful, the technology could significantly impact the continuous glucose monitoring segment, one of the fastest-growing areas in diabetes care.
Source: Glucotrack press release
